ESTABLISHED 2024 A CIVIC RECORD OF ACTIONS TAKEN AGAINST THE AMERICAN PEOPLE — AND HOW WE RESTORE THEM May 17, 2026
A nonpartisan civic restoration project

UndoTrump.com

★   ★   ★

Tracking every rollback, reversal, and overreach — and the path back to the America we know.

1,053
Actions Tracked
816
Still Active
29
In the Courts
32
Restored
482
Days Tracking

🏥 Healthcare

55 Actions  ·  Page 4 of 6
Active

Executive Order 13910: Preventing Hoarding of Health and Medical Resources

On March 23, 2020, President Trump signed Executive Order 13910, authorizing the Department of Health and Human Services to use the Defense Production Act to prevent hoarding and price gouging of health and medical resources needed for COVID-19 response. The order directed federal agencies to take action against the accumulation and retention of scarce health and medical resources, and established enforcement mechanisms for violations. The confirmed effect was to give federal authorities legal tools to address supply chain disruptions and ensure allocation of ventilators, personal protective equipment, and other critical medical supplies during the pandemic.

Expired

Federal Support for National Guard COVID-19 Response

On March 22, 2020, the Trump administration issued a memorandum (2020-06476) directing federal support for governors' deployment of the National Guard to respond to the COVID-19 pandemic. The memorandum authorized the use of National Guard troops under state control for COVID-19 related missions including staffing testing sites, assisting with hospital operations, and supporting supply distribution. The confirmed direct effect was the mobilization of National Guard personnel in multiple states to assist with pandemic response operations.

Expired

Executive Order 13909: Health and Medical Resources COVID-19 Response

Executive Order 13909 was signed on March 18, 2020, directing the prioritization and allocation of health and medical resources to respond to COVID-19 spread. The order invoked the Defense Production Act to enable the federal government to require private manufacturers to produce medical supplies and equipment needed for pandemic response. The order authorized federal officials to requisition ventilators, personal protective equipment, and other medical resources from private manufacturers and direct their distribution to areas with greatest need.

Expired

Expanded State-Approved Diagnostic Tests During COVID-19

On March 13, 2020, the Trump administration signed Memorandum 2020-05793 authorizing states to approve diagnostic tests for COVID-19 without prior federal clearance. The memorandum allowed state health departments to validate and deploy tests more rapidly than the standard FDA approval process. This expanded the number of available COVID-19 tests Americans could access during the early pandemic period.

Active

Declaration of National Emergency for COVID-19 Outbreak

President Trump signed Proclamation 2020-5794 on March 13, 2020, declaring a national emergency concerning the novel coronavirus disease (COVID-19) outbreak. The proclamation invoked the National Emergencies Act and the Stafford Act, enabling the federal government to mobilize resources, waive certain regulations, and authorize emergency funding for pandemic response. The declaration activated emergency powers that allowed FEMA to coordinate disaster relief, permitted the Secretary of Health and Human Services to waive Medicare requirements, and authorized the use of the Defense Production Act to manufacture medical supplies.

Expired

Memorandum authorizing general use respirators during COVID-19

On March 11, 2020, President Trump signed Memorandum 2020-05580 directing the Food and Drug Administration to allow manufacturers to produce general use respirators (non-medical masks and coverings) without prior approval. The memorandum removed regulatory barriers to expand respirator availability during the COVID-19 pandemic. This enabled broader civilian access to respiratory protection equipment during the early pandemic response.

Expired

Proclamation suspending entry of certain persons due to COVID-19 transmission risk

On March 11, 2020, President Trump signed Proclamation 10578 suspending the entry of foreign nationals who had been physically present in designated countries within 14 days prior to entry into the United States, citing COVID-19 transmission risk. The proclamation applied restrictions to travelers from Iran, Italy, South Korea, and certain regions of China. The order affected travel to the United States for foreign nationals from these areas, while U.S. citizens and permanent residents were generally permitted entry with health screening.

Active

Delegation of Authority to Re-establish Presidential Advisory Council on Antibiotic-Resistant Bacteria

On March 3, 2020, President Trump signed a memorandum delegating authority to re-establish the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. The council had previously been allowed to expire and this action restored its establishment and operational authority. The council advises the federal government on strategies and policies related to antibiotic resistance, which affects treatment options for bacterial infections in Americans.

Expired

American Heart Month Proclamation 2020

President Trump signed Proclamation 2020-02427 on January 31, 2020, designating February 2020 as American Heart Month. The proclamation calls for increased awareness of cardiovascular disease and encourages Americans to adopt healthier lifestyle practices. This is an annual proclamation with no binding regulatory effect on Americans.

Partially Undone

Executive Order 13890: Medicare Payment and Program Changes

President Trump signed Executive Order 13890 on October 3, 2019, directing the Department of Health and Human Services to modify Medicare payment policies and drug pricing negotiations. The order instructed HHS to implement changes to Medicare payment rates for certain services and to advance drug price negotiations. The confirmed direct impact included modifications to Medicare reimbursement structures that affected healthcare provider payments and drug pricing mechanisms within the Medicare program.